Ocular Therapeutix Receives CRL from FDA for its NDA for DEXTENZA for the Treatment of Post-Surgical Ocular Pain, No Efficacy Or Safety Issues Raised By FDA; Outstanding Items Due To Manufacturing Process & Controls
Paul Quintaro